Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    MA02 - RET and Novel Combinations of Osimertinib

    • 09:30 - 10:30
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      MA02.08 - Discussant

      10:15 - 10:30  |  Presenter: Adrian G. Sacher

      • Abstract

      No abstract available for this presentation

  • +

    FP01 - Early Stage/Localized Disease/Ablative Therapies

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Early Stage/Localized Disease/Ablative Therapies
    • +

      FP01.03 - Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC

      00:00 - 00:00  |  Presenter: Sabine Schmid

      • Abstract

      Loading...

  • +

    FP05 - Liquid Biopsy and Other Non-invasive Diagnostic Modalities

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities
    • +

      FP05.02 - A Biomarker-Directed, Multi-Center Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Lung Cancer

      00:00 - 00:00  |  Presenter: Valsamo Anagnostou

      • Abstract

      Loading...

  • +

    FP12 - Predictive Tumor Based Assays/Biomarkers/Pathology

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      FP12.01 - PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC

      00:00 - 00:00  |  Presenter: Sally CM Lau

      • Abstract

      Loading...

    • +

      FP12.07 - Clinico-demographic Factors, EGFR status and their association with Stage at Diagnosis in Lung Adenocarcinoma Patients

      00:00 - 00:00  |  Presenter: Joshua E Herman

      • Abstract

      Loading...

  • +

    P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P45.05 - Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival

      00:00 - 00:00  |  Presenter: Sally CM Lau

      • Abstract

      Loading...

    • +

      P45.07 - Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK+ NSCLC

      00:00 - 00:00  |  Presenter: Sabine Schmid

      • Abstract

      Loading...

    • +

      P45.09 - Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada

      00:00 - 00:00  |  Presenter: Simren Chotai

      • Abstract

      Loading...

  • +

    P48 - Novel Therapeutics and Targeted Therapies - EGFR

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P48.05 - Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?

      00:00 - 00:00  |  Presenter: Miguel Garcia

      • Abstract

      Loading...

  • +

    P59 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - Targeted Therapies Biomarkers

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      P59.17 - EGFR Mutation Status, Liver Metastasis, and Overall Survival in Advanced Lung Adenocarcinoma Patients

      00:00 - 00:00  |  Presenter: Preet Walia

      • Abstract

      Loading...

  • +

    OA08 - Moving Beyond New Drugs: What Else Matters?

    • 09:30 - 10:30
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Health Services Research/Health Economics
    • +

      OA08.04 - Validation of Scalable, Automated Data Extraction in an Advanced Lung Cancer Patient Population

      10:00 - 10:10  |  Presenter: Marie-pier Gauthier

      • Abstract

      Loading...

  • +

    MA08 - Driver Mutations and Immune Profiles in Early Stage NSCLC

    • 12:00 - 13:00
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Early Stage/Localized Disease/Ablative Therapies
    • +

      MA08.02 - Outcomes of Early Stage ALK-positive NSCLC Patients in a Real-World Cohort

      12:05 - 12:10  |  Presenter: Sabine Schmid

      • Abstract

      Loading...

  • +

    MA14 - Pathologic Patterns, Genomic Alterations and Targeted Therapies in NSCLC

    • 18:45 - 19:45
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      MA14.03 - Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib

      18:55 - 19:00  |  Presenter: Ferdinandos Skoulidis

      • Abstract

      Loading...